A Phase 3 interventional study of Triptorelin in Central Precocious Puberty, sponsored by Debiopharm International SA. Completed at 13 sites in 3 countries. Open to participants aged 2 Years to 9 Years. Per ClinicalTrials.gov, last updated 2017-07-28.
Sponsored by Debiopharm International SA (part of Debiopharm) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Puberty, Precocious with a site in United States — 4 open to participants now, 5 under way, 1 of them phase 3. Puberty, Precocious · United States.
Among the 21 studies in Puberty, Precocious with a site in United States, this one is the 10th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2012, is one of 8 in phase 3, and was the 13th registered.
75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.
Browse Puberty, Precocious studies →4 of the 21 studies in Puberty, Precocious with a site in United States are open now. Recruiting first, the newest first:
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 8–99
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 6 wk–120 yrs
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 1 days–99 yrs
Atossa Therapeutics, Inc. · Sites in United States
Ages 4–9 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 2 Years to 9 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 1982; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 64 across 47 interventional studies indexed under Puberty, Precocious.
Median enrollment 55 across the 15 interventional studies, 850 across the 5 observational. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Debiopharm International SA, one of the names counted as Debiopharm. Under that name alone:
Debiopharm International SA is the lead sponsor of 51 studies on the registry; 6 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Debiopharm has 2 studies filed under Puberty, Precocious — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Puberty, Precocious with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg 6-month formulation in 44 patients suffering from central precocious puberty. The total study duration per patient will be 12 months (48 weeks).
Inclusion criteria:
Non-inclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169
Drug: Triptorelin
Powder and solution for solution for injection
Also known as: Trelstar
Percentage of Children With Luteinizing Hormone (LH) Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Month 6
This is a lab test to see what percentage of participants were returned to normal before-puberty levels at Month 6.
Time frame: Month 6
Percentage of Children With LH Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Months 1, 2, 3, 9 and 12
This is a lab test to see what percentage of children were returned to normal before-puberty levels by the drug at each time point.
Time frame: at Months 1, 2, 3, 9 and 12
Percentage of Children Maintaining LH Suppression at Prepubertal Levels 30 Minutes After Leuprolide Stimulation From Month 6 to 12
This is a lab test to see what percentage of children stayed at the normal before-puberty level from month 6 to month 12.
Time frame: from Month 6 to 12
Percentage of Children With LH Suppression (LH ≤ 4 IU/L)30 Minutes After Leuprolide Stimulation at Months 1, 2, 3, 6, 9 and 12
This is a lab test to see what percentage of children were returned to lower than normal before-puberty levels by the drug at each time point.
Time frame: at Months 1, 2, 3, 6, 9 and 12
Percentage of Children Maintaining LH Suppression at </= 4 IU/L 30 Minutes After Leuprolide Stimulation From Month 6 to 12
This is a lab test to see what percentage of children stayed at the lower than normal before-puberty level from month 6 to month 12.
Time frame: from Month 6 to 12
Change From Baseline in Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) at Months 1, 2, 3, 6, 9, and 12
Time frame: Baseline to Months 1, 2, 3, 6, 9, and 12
Change From Baseline in Estradiol Levels at Months 1, 2, 3, 6, 9, and 12
Time frame: Baseline to Months 1, 2, 3, 6, 9, and 12
Change From Baseline in Testosterone Levels at Months 1, 2, 3, 6, 9, and 12
Time frame: Baseline to Months 1, 2, 3, 6, 9, and 12
Percentage of Children With Prepubertal Estradiol or Testosterone Levels at Months 1, 2, 3, 6, 9, and 12
Time frame: at Months 1, 2, 3, 6, 9, and 12
Percentage of Children Without Higher Basal LH and Estradiol or Testosterone
Time frame: at 2 days after second triptorelin injection (Day 171)
Change From Baseline in Height-for-age Z-score Per 2000 CDC Growth Charts at Months 6 and 12
Time frame: Baseline to Months 6 and 12
Change From Baseline in Height-for-age Percentile Per 2000 CDC Growth Charts at Months 6 and 12
Time frame: Baseline to Months 6 and 12
Change From Baseline in Growth Velocity at Months 6 and 12
Time frame: Baseline to Months 6 and 12
Percentage of Participants Without Bone Age / Chronological Age Ratio Increase From Baseline at Months 6 and 12
Time frame: Baseline to Months 6 and 12
Percentage of Children Achieving Stabilization of Sexual Maturation at Months 6 and 12
Time frame: at Months 6 and 12
Percentage of Girls With Regression of Uterine Length Compared to Baseline at Months 6 and 12
Time frame: Baseline to Months 6 and 12
Percentage of Boys With Absence of Progression of Testis Volumes Compared to Baseline at Months 6 and 12
Time frame: Baseline to Months 6 and 12
Intention to treat, defined as all participants enrolled
| Milestone | Children |
|---|---|
| Started | 44 |
| Completed | 44 |
| Not completed | 0 |
This is a lab test to see what percentage of participants were returned to normal before-puberty levels at Month 6.
| percentage of participants | Children |
|---|---|
| Percentage of Children With Luteinizing Hormone (LH) Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Month 6 | 93.18 (81.34 to 98.57) |
This is a lab test to see what percentage of children were returned to normal before-puberty levels by the drug at each time point.
| percentage of participants | Children |
|---|---|
| Month 1 | 95.45 |
| Month 2 | 95.45 |
| Month 3 | 95.45 |
| Month 9 | 95.45 |
| Month 12 | 97.73 |
This is a lab test to see what percentage of children stayed at the normal before-puberty level from month 6 to month 12.
| percentage of participants | Children |
|---|---|
| Percentage of Children Maintaining LH Suppression at Prepubertal Levels 30 Minutes After Leuprolide Stimulation From Month 6 to 12 | 93.18 |
This is a lab test to see what percentage of children were returned to lower than normal before-puberty levels by the drug at each time point.
| percentage of participants | Children |
|---|---|
| Month 1 | 95.45 |
| Month 2 | 95.45 |
| Month 3 | 93.18 |
| Month 6 | 90.91 |
| Month 9 | 93.18 |
| Month 12 | 97.73 |
This is a lab test to see what percentage of children stayed at the lower than normal before-puberty level from month 6 to month 12.
| percentage of participants | Children |
|---|---|
| Percentage of Children Maintaining LH Suppression at </= 4 IU/L 30 Minutes After Leuprolide Stimulation From Month 6 to 12 | 90.91 |
| IU/L | All Children Luteinizing Hormone | All Children Follicle Stimulating Hormone |
|---|---|---|
| at Month 1 | -25.21 ± 20.28 | -8.85 ± 4.15 |
| at Month 2 | -25.25 ± 20.41 | -8.80 ± 4.20 |
| at Month 3 | -25.17 ± 20.53 | -8.13 ± 4.26 |
| at Month 6 | -23.06 ± 22.17 | -6.66 ± 4.61 |
| at Month 9 | -25.24 ± 20.49 | -7.87 ± 4.27 |
| at Month 12 | -25.15 ± 20.50 | -6.99 ± 4.63 |
| ng/L | Girls |
|---|---|
| at Month 1 | -31.87 ± 27.82 |
| at Month 2 | -31.24 ± 31.80 |
| at Month 3 | -32.15 ± 28.65 |
| at Month 6 | -28.18 ± 31.26 |
| at Month 9 | -30.08 ± 27.44 |
| at Month 12 | -29.74 ± 28.24 |
| ng/dL | Boys |
|---|---|
| at Month 1 | -306.96 ± 184.06 |
| at Month 2 | -290.70 ± 214.81 |
| at Month 3 | -319.20 ± 177.04 |
| at Month 6 | -317.62 ± 178.11 |
| at Month 9 | -315.54 ± 183.98 |
| at Month 12 | -301.86 ± 205.29 |
| percentage of participants | Children | Girls | Boys |
|---|---|---|---|
| at Month 1 | 86.36 | 87.18 | 80.00 |
| at Month 2 | 88.37 | 89.47 | 80.00 |
| at Month 3 | 93.18 | 92.31 | 100.00 |
| at Month 6 | 81.82 | 79.49 | 100.00 |
| at Month 9 | 81.82 | 82.05 | 80.00 |
| at Month 12 | 79.55 | 79.49 | 80.00 |
| percentage of participants | AOC Subset |
|---|---|
| Percentage of Children Without Higher Basal LH and Estradiol or Testosterone | 13.64 |
| Z-score | Children |
|---|---|
| at Month 6 | 0.05 ± 0.20 |
| at Month 12 | 0.00 ± 0.27 |
| percentile | Children |
|---|---|
| at Month 6 | 1.01 ± 3.21 |
| at Month 12 | 0.91 ± 4.39 |
| cm/year | Children |
|---|---|
| at Month 6 | 6.84 ± 2.33 |
| at Month 12 | 6.05 ± 1.7 |
| percentage of participants | Children |
|---|---|
| at Month 6 | 63.64 |
| at Month 12 | 95.45 |
| percentage of participants | Children |
|---|---|
| at Month 6 | 90.91 |
| at Month 12 | 88.64 |
| percentage of participants | Girls |
|---|---|
| at Month 6 | 69.23 |
| at Month 12 | 76.92 |
| percentage of participants | Boys |
|---|---|
| at Month 6 | 100.00 |
| at Month 12 | 100.00 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Children | — | 1/44 (2.3%) | 20/44 (45.5%) |
| Event | Children |
|---|---|
| Device related infectionInfections and infestations | 1/44 |
| Event | Children |
|---|---|
| HeadacheNervous system disorders | 6/44 |
| NasopharyngitisInfections and infestations | 6/44 |
| Upper respiratory tract infectionInfections and infestations | 4/44 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/44 |
| GastroenteritisInfections and infestations | 3/44 |
Intention to treat, defined as all participants enrolled
| Age, Categorical(Participants) | Children |
|---|---|
| <=18 years | 44 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Continuous(years) | Children |
|---|---|
| Mean | 7.41 ± 1.28 |
| Sex: Female, Male(Participants) | Children |
|---|---|
| Female | 39 |
| Male | 5 |
| Region of Enrollment(participants) | Children |
|---|---|
| United States | 28 |
| Mexico | 1 |
| Chile | 15 |
The record gives a start of Apr 2012, a primary completion of Aug 2013 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 2 years 1 month after primary completion. A results delay was requested in Aug 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triptorelin